KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to -$136.5 million.

  • Novavax's Cash from Investing Activities fell 527.83% to -$136.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.3 million, marking a year-over-year increase of 112.67%. This contributed to the annual value of -$204.0 million for FY2024, which is 246.97% down from last year.
  • Per Novavax's latest filing, its Cash from Investing Activities stood at -$136.5 million for Q3 2025, which was down 222.89% from $111.1 million recorded in Q2 2025.
  • Novavax's Cash from Investing Activities' 5-year high stood at $144.0 million during Q4 2024, with a 5-year trough of -$372.7 million in Q2 2024.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$9.1 million (2023), whereas its average is -$32.9 million.
  • Data for Novavax's Cash from Investing Activities shows a peak YoY increase of 1,686.33% (in 2024) and a maximum YoY decrease of 4,691.19% (in 2024) over the last 5 years.
  • Over the past 5 years, Novavax's Cash from Investing Activities (Quarterly) stood at -$16.4 million in 2021, then slumped by 34.83% to -$22.1 million in 2022, then soared by 58.86% to -$9.1 million in 2023, then skyrocketed by 1,686.33% to $144.0 million in 2024, then tumbled by 527.83% to -$136.5 million in 2025.
  • Its Cash from Investing Activities was -$136.5 million in Q3 2025, compared to $111.1 million in Q2 2025 and -$73.3 million in Q1 2025.